Patents Assigned to Wyeth
  • Polysaccharides of Helicobacter pylori
    Publication number: 20050118197
    Abstract: The invention is directed to immunogenic compositions comprising polysaccharides and polysaccharide-protein conjugates that are useful to induce or detect the production of antibodies specific for H. pylori. The invention is also directed to methods of purifying the H. pylori polysaccharides from bacteria. The polysaccharide may be incorporated into an immunogenic composition or used in vitro to assay for the presence of H. pylori antibodies in a sample or biological fluid.
    Type: Application
    Filed: October 28, 2004
    Publication date: June 2, 2005
    Applicant: Wyeth Holdings Corporation
    Inventors: Mario Monteiro, James Fulginiti, Deborah Dilts
  • Substituted indoles
    Publication number: 20050119327
    Abstract: The present invention relates generally to substituted indoles such as substituted 1H-indole-2-carboxylic acid derivatives, and methods of using them.
    Type: Application
    Filed: September 23, 2004
    Publication date: June 2, 2005
    Applicant: WYETH
    Inventor: Baihua Hu
  • Methods of treating atherosclerosis using NF-kB inhibitors
    Publication number: 20050119324
    Abstract: The present invention concerns a method of treating atherosclerosis by diagnosing that a person is in need of treatment for atherosclerosis and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-?, estrogen receptor ER-?, or both ER-? and ER-? estrogen receptors with a substantial absence of creatine kinase stimulation. In certain preferred embodiments, the administration is substantially without uterotropic activity.
    Type: Application
    Filed: September 23, 2004
    Publication date: June 2, 2005
    Applicant: Wyeth
    Inventors: Douglas Harnish, Christopher Chadwick
  • Humanized antibodies that recognize beta amyloid peptide
    Publication number: 20050118651
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include antibodies, e.g., humanized antibodies.
    Type: Application
    Filed: June 1, 2004
    Publication date: June 2, 2005
    Applicants: Neuralab Limited, Wyeth
    Inventors: Guriq Basi, Jose Saldanha, Frederique Bard
  • Methods of treating inflammatory bowel disease using NF-kB inhibitors
    Publication number: 20050119276
    Abstract: The present invention concerns a method of treating inflammatory bowel disease by diagnosing that a person is in need of treatment for inflammatory bowel disease and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-?, estrogen receptor ER-?, or both ER-? and ER-? estrogen receptors with a substantial absence of creatine kinase stimulation. In certain preferred embodiments, the administration is substantially without uterotropic activity.
    Type: Application
    Filed: September 23, 2004
    Publication date: June 2, 2005
    Applicant: Wyeth
    Inventors: Douglas Harnish, Christopher Chadwick, James Keith
  • Substituted aryloximes
    Publication number: 20050119326
    Abstract: The present invention relates to substituted indole oximes and methods of using them.
    Type: Application
    Filed: September 23, 2004
    Publication date: June 2, 2005
    Applicant: WYETH
    Inventors: Lisa Havran, John Butera, Hassan Elokdah, Douglas Jenkins, Eric Gundersen
  • 74-kilodalton outer membrane protein from Moraxella catarrhalis
    Patent number: 6899885
    Abstract: A protein from M. catarrhalis, designated the 74 kD protein, is isolated and purified. The 74 kD protein has an amino-terminal amino acid sequence which is conserved among various strains of M. catarrhalis. The protein has a molecular weight of approximately 74.9 kD as measured on a 10% SDS-PAGE gel, while its molecular weight as measured by mass spectrometry is approximately 74 kD. The 74 kD protein is used to prepare a vaccine composition which elicits a protective immune response in a mammalian host, to protect the host against disease caused by M. catarrhalis.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: May 31, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Dexiang Chen, Karl R. VanDerMeid, John C. McMichael, Vicki L. Barniak
  • Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
    Patent number: 6900200
    Abstract: This invention provides novel substituted tricyclic carboxamides which act as oxytocin receptor competitive antagonists, as well as methods of their manufacture, pharmaceutical compositions and methods of their use in treatment, inhibition, suppression or prevention of preterm labor, dysmenorrhea and endometritis, suppression of labor at term prior to caesarean delivery, and to facilitate antinatal transport to a medical facility. These compounds are also useful in enhancing fertility rates, enhancing survival rates and synchronizing estrus in farm animals; and may be useful in the prevention and treatment of disfunctions of the oxytocin system in the central nervous system including obsessive compulsive disorder (OCD) and neuropsychiatric disorders.
    Type: Grant
    Filed: April 10, 2002
    Date of Patent: May 31, 2005
    Assignee: Wyeth
    Inventors: Amedeo Arturo Failli, Jay Scott Shumsky, Thomas Joseph Caggiano, Joseph P. Sabatucci, Eugene John Trybulski, Kevin Anthony Memoli, William Jennings Sanders
  • Compositions containing pipercillin and tazobactam useful for injection
    Patent number: 6900184
    Abstract: The invention pertains to pharmaceutical compositions of Zosyn® piperacillin with tazobactam in the presence of a buffer, preferably citrate, a particulate formation inhibitor, preferably EDTA optionally an aminoglycoside which when frozen and thawed or lyophilized and reconstituted reform a solution which has decreased particulate formation.
    Type: Grant
    Filed: April 14, 2003
    Date of Patent: May 31, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Jonathan Marc Cohen, Syed M. Shah, Christian Luther Ofslager, Mahdi Fawzi
  • Dihydrodipyrazolopyridinone inhibitors of B7-1
    Patent number: 6900223
    Abstract: The present invention provides a compound of formula I and the use thereof for the immunotherapeutic treatment of transplant rejection, autoimmune disease or graft vs. host disease.
    Type: Grant
    Filed: July 28, 2003
    Date of Patent: May 31, 2005
    Assignee: Wyeth
    Inventors: Neal Jeffrey Green, Steve Yikkai Tam, Jason Shaoyun Xiang, Audrey Molina Davies, Lihren Chen, Gary Paul Stack
  • Substituted indoles
    Publication number: 20050113438
    Abstract: The present invention relates generally to substituted indoles and methods of using them.
    Type: Application
    Filed: September 23, 2004
    Publication date: May 26, 2005
    Applicant: WYETH
    Inventors: Baihua Hu, James Jetter
  • Substituted pyrrole-indoles
    Publication number: 20050113439
    Abstract: The present invention relates generally to substituted pyrrole-indoles such as substituted pyrrole-indoles, and methods of using them.
    Type: Application
    Filed: September 23, 2004
    Publication date: May 26, 2005
    Applicant: WYETH
    Inventor: Baihua Hu
  • Methods of treating rheumatoid arthritis using NF-kB inhibitors
    Publication number: 20050113405
    Abstract: The present invention concerns a method of treating rheumatoid arthritis by diagnosing that a person is in need of treatment for rheumatoid arthritis and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-?, estrogen receptor ER-?, or both ER-? and ER-? estrogen receptors with a substantial absence of creatine kinase stimulation. In certain embodiments, the administration is with a substantial absence of uterotropic activity.
    Type: Application
    Filed: September 23, 2004
    Publication date: May 26, 2005
    Applicant: Wyeth
    Inventors: Douglas Harnish, Christopher Chadwick, James Keith
  • Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
    Publication number: 20050113436
    Abstract: Compounds of formula (I) and II) are provided wherein: X is an alkali metal or a basic amine moiety; R1 is alkyl, cycloalkyl, —CH2-cycloalkyl, pyridinyl, —CH2-pyridinyl, phenyl or benzyl, the rings of these groups being optionally substituted; R2 is H, halogen, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, —CH2-cycloalkyl, —NH2, or —NO2; R3 is phenyl, benzyl, benzyloxy, pyridinyl, or —CH2-pyridinyl, with the rings of these groups being optionally substituted; or a pharmaceutically acceptable salt or ester form thereof, as well as pharmaceutical compositions and methods using these compounds as inhibitors of plasminogen activator inhibitor-1 (PAI-1) and as therapeutic compositions for treating conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis.
    Type: Application
    Filed: December 9, 2003
    Publication date: May 26, 2005
    Applicant: Wyeth
    Inventors: Hassan Elokdah, David Li
  • Substituted oxadiazolidinediones
    Publication number: 20050113428
    Abstract: The present invention relates generally to substituted oxadiazolidinediones and methods of using them.
    Type: Application
    Filed: September 23, 2004
    Publication date: May 26, 2005
    Applicant: WYETH
    Inventors: Ariamala Gopalsamy, Scott Kincaid
  • Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands
    Publication number: 20050107431
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of a CNS disorder relating to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: October 8, 2004
    Publication date: May 19, 2005
    Applicant: Wyeth
    Inventor: Lynne Greenblatt
  • Endoparasiticidal gel composition
    Publication number: 20050106202
    Abstract: A homogenous, clear, veterinary gel composition which has a broad spectrum of efficacy against endoparasites over a prolonged period of time and which allows for higher concentrations of a mixture of parasiticidal agents in a single application. This composition is useful for treating and controlling endoparasiticidal infection and infestation in a homeothermic animal.
    Type: Application
    Filed: December 24, 2004
    Publication date: May 19, 2005
    Applicant: WYETH
    Inventors: Shobhan Sabnis, Jon Hayes, Jack Zupan
  • Processes for the preparation of N-substituted phthalimides
    Publication number: 20050107618
    Abstract: The present invention describes a process for preparing N-substituted phthalimides of Formula I which are widely useful as intermediates in the preparation of organic compounds such as pharmaceuticals.
    Type: Application
    Filed: November 16, 2004
    Publication date: May 19, 2005
    Applicant: Wyeth
    Inventors: Yanzhong Wu, Panolil Raveendranath
  • Endoparasiticidal gel composition
    Patent number: 6893652
    Abstract: A homogenous, clear, veterinary gel composition which has a broad spectrum of efficacy against endoparasites over a prolonged period of time and which allows for higher concentrations of a mixture of parasiticidal agents in a single application. This composition is useful for treating and controlling endoparasiticidal infection and infestation in a homeothermic animal.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: May 17, 2005
    Assignee: Wyeth
    Inventors: Shobhan S. Sabnis, Jon Hayes, Jack A. Zupan
  • Serotonergic agents with long-acting in vivo effects
    Patent number: 6894053
    Abstract: Compounds of the formula have a long duration of action and are useful for the treatment of chronic diseases resulting from the dysfunction of the serotonergic 5-HT1A system, such as schizophrenia and other psychotic disorders such as paranoia and mano-depressive illness.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: May 17, 2005
    Assignee: Wyeth
    Inventors: Wayne E. Childers, Michael G. Kelly, Lee E. Schechter, Sharon J. Rosenzweig-Lipson